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644Objective: Aortic stenosis is the most common valvular pathology in the elderly. Transcatheter aortic valve
replacement has emerged as a safe and feasible alternative for high-risk patients. However, a significant number
of patients are still not transcatheter aortic valve replacement candidates because of poor peripheral access and
chest pathology. We report the use of alternative access options for such patients.
Methods: Seven patients who had poor peripheral access and chest pathology had transcatheter aortic valve
replacement using alternative access techniques. Five patients had the valve delivered by direct cannulation
of the aorta via a mini-sternotomy, and 1 patient had the valve delivered via a mini–right thoracotomy. In 1
patient, the right subclavian artery was cannulated. Intraprocedural and 30-day outcome data were analyzed.
Results: Themean age of patients was 85.00 9.59 years, with a Society of Thoracic Surgeons score of 16.81%
 6.87% and logistic European System for Cardiac Operative Risk Evaluation of 21.59% 8.46%. Procedural
success was 100%. Procedural and 30-day mortality were zero. There were no access-related complications or
neurologic events. Two patients had worsening renal function that did not require dialysis. All patients were
discharged with a median hospital stay of 7 days. In our experience of 138 transapical or alternative access
patients, 7 died (5%) and for 257 transfemoral patients, 1 died (0.4%).
Conclusions: Despite the high surgical risk of the study population, these techniques had excellent outcome
with no mortality and acceptable morbidity. With the use of currently available technologies, these approaches
are promising and offer alternative options in patients with no access and prohibitive chest pathology or pulmo-
nary function. (J Thorac Cardiovasc Surg 2014;147:644-51)Aortic stenosis is the most common valvular pathology in
the elderly, with an estimated prevalence of 4.5% in adults
aged 75 years or more.1 The outcome of medically managed
symptomatic aortic stenosis is dismal, with approximately
50% of the patients not surviving beyond the first year.2
Surgical aortic valve replacement (SAVR) is the gold stan-
dard in the treatment of symptomatic aortic stenosis and has
been proven to have both symptomatic and survival bene-
fits.3 However, because of the typical elderly patient with
many comorbidities, a large number of patients with aortic
stenosis are not referred for surgery because they are con-
sidered inoperable or are at very high risk.
Since the first successful clinical implantation by Cribier
and colleagues4 in 2002, transcatheter aortic valve replace-
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The Journal of Thoracic and Cardiovascular Surginoperable and high-risk patient. Currently, the 2 routes
by which the valve is delivered are the retrograde transfe-
moral or antegrade transapical approach. However, there
remain a considerable number of patients who are not can-
didates for either approach because of poor vascular access,
poor pulmonary function, or chest pathology.
This report describes our initial clinical experience in 7
patients using a retrograde approach of TAVR by direct can-
nulation of the ascending aorta or the subclavian artery in
patients who had poor peripheral vascular access, respira-
tory function, and chest pathology.MATERIALS AND METHODS
Patient Selection
Patients who are considered inoperable or very high risk for SAVR are
currently only considered for TAVR at the Cleveland Clinic. A multidisci-
plinary team consisting of cardiac surgeons and cardiologists assess and
discuss each patient and decide on the optimal approach for each patient
given the patient demographics and risk factors.
Those selected for a percutaneous approach are then assessed for the ret-
rograde transfemoral or antegrade transapical approach via a left thoracot-
omy. However, patients in this report were not suitable for either approach
for reasons that will be described.
Patient Risk Level Stratification
In addition to clinical assessment of patients, comorbidities, and risk
factors, risk scores were used. Both the Society of Thoracic Surgery score
and the European System for Cardiac Operative Risk Evaluation wereery c February 2014
Abbreviations and Acronyms
AV ¼ aortic valve
BAV ¼ balloon aortic valvuloplasty
CPB ¼ cardiopulmonary bypass
FEV1 ¼ forced expiratory volume in 1 second
ICU ¼ intensive care unit
SAVR ¼ surgical aortic valve replacement
TAVR ¼ transcatheter aortic valve replacement
TEE ¼ transesophageal echocardiography
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and the numbers were not taken as absolute.
Preoperative Workup
All patients underwent preoperative transthoracic echocardiography
and transesophageal echocardiography (TEE). They also underwent diag-
nostic coronary angiogram. Workup also included pulmonary function test
with diffusion capacity.
For assessment of the central aorta and peripheral arteries, patients had
computed tomography angiography that included the ascending, arch, thor-
acoabdominal aorta, iliac, and femoral arteries. Assessment of tortuosity of
the aorta and degree of stenosis, calcification, and aneurysm was per-
formed. Measurements of different sections of the peripheral and central
aorta were performed to assess whether the valve delivery sheath could
be safely accommodated.
Procedure
All procedures were performed under general anesthesia in a hybrid-
operating suite. The team consisted of cardiac surgeons, interventional car-
diologists, and cardiac anesthesiologists. Cardiac perfusionists with
a primed cardiopulmonary bypass (CPB) machine were on standby in all
cases. Both fluoroscopy and TEE were used as imaging modalities during
the procedure. TEEwas used to measure the aortic annulus to size the valve
to be deployed and to give a dynamic view of the procedure.
Five patients had access to the ascending aorta via an upper J inci-
sion hemisternotomy, 1 via a mini–right anterior thoracotomy and 1
through the left subclavian artery. In the patients with an upper hemi-
sternotomy, an 8-cm skin incision was performed in the midline starting
just above the manubriosternal angle. Preoperatively, by using com-
puted tomography scans, the decision was made whether to cut into
the right third or fourth intercostal space depending on the position of
the aortic annulus.
A regular sternal saw was used to split the sternum at midline starting at
the sternal notch. The sternal cut is deviated to the desired right intercostal
space forming a J-incision. A mini-sternal retractor was used to spread the
split sternum. The pericardium was opened and retracted with stay sutures
to the chest wall allowing good exposure of the aorta. In 1 patient (patient
4), the approach was via a mini–right anterior thoracotomy. A 4-cm inci-
sion was made over the right second intercostal space just lateral to the ster-
num. The third rib was transected at the medial end to allow better exposure
of the space. A mini–rib spreader was used to open the intercostal space.
The pericardium was opened, and the edges were tucked to the chest
wall. In patient 7, the access was via the left subclavian artery. A 5-cm
long incision was made just across the mid-clavicular line approximately
2 cm below the clavicle. The subclavian artery was exposed, and
a 10-mm Dacron graft was anastomosed to a longitudinal arteriotomy.
An Edwards (Edwards Lifesciences Inc, Irvine, Calif) delivery sheath
was secured to the Dacron graft and acted as a control valve.The Journal of Thoracic and CaIn our initial experience and in anticipation of any emergency situation
requiring the heart-lung machine, we have obtained generous exposure to
easily access the aortic valve (AV). A unilateral cut-down of the femoral
artery and vein also was performed. Transvenous pacer wires were intro-
duced and passed via the femoral vein into the right atrium. The patient
received 100 U/Kg of unfractionated heparin, and the activated clotting
time was maintained at more than 300 seconds until the end of the proce-
dure. Heparin was reversed 1:1 with protamine at the end of the case before
closing the chest.
An area denude of any evidence of calcification was selected in the
ascending aorta. Care was taken to select the appropriate angle and dis-
tance from the aortic annulus to allow manipulation of the valve sheath.
The best location is the upper one third of the ascending aorta because
this gives adequate length and better curving angle. A double purse
string was applied to the left lateral portion of the upper one third of
the ascending aorta. Access into the aorta was gained with an 18-G nee-
dle and a starter wire. The needle was exchanged for a short 5F sheath,
and the starter wire was exchanged with a 0.035-inch straight soft-tip
hydrophilic glide wire. Under fluoroscopy, the AV was crossed with
a glide wire and 5F catheter. Simultaneous pressure recordings of the
left ventricle and aorta were obtained. The wire was exchanged with
an extra stiff wire with a soft curved tip. The 5F sheath was then ex-
changed with the Edwards delivery sheath. A 20-mm balloon dilation
catheter was passed over the wire and positioned across the stenotic
AV. Under rapid ventricular pacing and ventilator arrest, AV balloon an-
gioplasty was performed. These steps were the same in the subclavian
approach.
All patients received SAPIEN (Edwards Lifesciences Inc) percutaneous
AVs. The valves used in these cases were loaded in a retrograde fashion as
those used in the transfemoral approach. By using a combination of fluo-
roscopy and TEE guidance, the valve was positioned at the desired level
across the AV. Under rapid ventricular pacing and ventilator arrest, the
AV was deployed. Our approach has been for a slow deployment of the
valve to allow adjustment of the position in case the valve moves while
being deployed.
The valve sheath was then removed and replaced with a pigtail. We per-
formed a root aortogram to assess for valvular and paravalvular regurgita-
tion. TEE was used to confirm position, measure gradients, and assess for
valvular and paravalvular regurgitation. After deployment, balloon dilation
of the valve was sometimes performed if there was evidence of significant
paravalvular leak.
A single chest tube was inserted in a para-aortic fashion, and the ster-
num was closed in the usual manner in cases with sternotomy and mini-
thoracotomy. If hemodynamic and respiratory status allowed, extubation
was attempted on all patients in the operating room after the procedure.
Statistical Evaluation
Continuous variables were reported as mean  standard deviation or
median with interquartile range given the small sample size. Categoric var-
iables are described as percentages. Paired t test was used to compare con-
tinuous variables.RESULTS
Demographic Characteristics
Table 1 summarizes the preoperative baseline character-
istics of the patients. The study population had a mean age
of 85.00 9.59 years. None of the patients were on dialysis,
and the mean creatinine was 1.41  0.55 mg/dL. All
patients were hypertensive and had peripheral vascular
disease, but none of them were diabetic and receiving
insulin.rdiovascular Surgery c Volume 147, Number 2 645
TABLE 1. Clinical characteristics
Clinical characteristics Patient 1 Patient 2 Patient 3
Age (y) 80 87 90
Sex M F F
Creatinine (mg/dL) 2.28 1.23 0.70
Dialysis N N N
BSA (m2) 1.89 1.64 1.50
HTN Y Y Y
PVD Y Y Y
DM on insulin N N N
FEV1 (L) 1.97 0.71 0.54
FVC (L) 3.34 0.96 0.56
NYHA IV III IV
CCS I I I
EF (%) 20 54 62
Pulmonary hypertension Mild Moderate Severe
Preoperative echocardiogram
AVA (cm2) 0.72 0.66 0.64
Peak AV gradient (mm Hg) 49 96 89
Mean AV gradient (mm Hg) 25 47 46
Valvular insufficiency 1þ AI 1þ AI, 1þ MR, 1þ TR 2þ AI, 3þ MR, 3þ TR
Comorbidities Atrial fibrillation, PVD PVD, RLD, HOCOM, scoliosis,
atrial fibrillation, Mobitz II,
PPM
Atrial fibrillation, gout, breast CA
(XRT)
Indications for alternative
approach
PVD, unable to pass sheath in
iliac artery
Home oxygen, severe lung
disease, PVD
Severe calcification and tortuosity
of aorta and iliac arteries,
severe lung disease, on home
oxygen
euroSCORE 25.10 14.59 20.05
STS score 18.17 18.74 17.85
SD, Standard deviation; BSA, body surface area; HTN, hypertension; PVD, peripheral vascular disease; DM, diabetes mellitus; FEV1, forced expiratory volume in 1 second;
FVC, forced vital capacity; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; EF, ejection fraction; AVA, aortic valve area; AV, aortic valve;
euroSCORE, European System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic Surgery; AI, aortic insufficiency; MR, mitral regurgitation; TR, tricuspid
regurgitation; HOCOM, hypertrophic obstructive cardiomyopathy; PPM, permanent pacemaker; CA, cancer; XRT, radiotherapy; s/p CABG, status post-coronary artery bypass
grafting; CRF, chronic renal failure; CVA, cerebrovascular accident; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity for
carbon monoxide; N/A, not available.
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(FEV1) less than 1 L/s, and the mean FEV1 was 1.60 
1.00. The mean forced vital capacity was 2.30  1.42 L
(range, 0.56-4.48l).
All patients except one did not have symptoms that were
attributed to coronary artery disease. Two of the patients
were in NewYork Heart Association class IV, and 5 patients
were in class III. All procedures were done on urgent basis
because of the patients’ presenting symptoms and history.
Preoperatively, the echocardiography characteristics
showed a mean ejection fraction of 45.14%  17.87%.
The AV stenosis was critical with an AV area mean of
0.62  0.13 cm2. The peak AV gradient was 74.86 
23.28 mm Hg, and the mean gradient was 41.43  10.45
mm Hg. Five patients had some mild degree of aortic insuf-
ficiency preoperatively, and 1 patient had moderate aortic
insufficiency preoperatively. One patient had moderate to
severe mitral regurgitation, and 2 patients had moderate to
severe tricuspid regurgitation.646 The Journal of Thoracic and Cardiovascular SurgAll patients had multiple comorbidities as indicated in
Table 1. The mean Society of Thoracic Surgery score for
the patients was 16.81%  6.87%, and the logistic euro-
HEART was 21.59%  8.46%.Intraoperative Results
Table 2 shows the intraoperative parameters. There was
100% success in valve deployment. The position of the
valve, as visualized by intraoperative TEE, was satisfactory
in all cases. There was no intraoperative emergency conver-
sion to SAVR. None of the patients required CPB for hemo-
dynamic compromise intraoperatively or intra-aortic
balloon pump postoperatively.
Fluoroscopy time was 18.86  7.39 minutes. Mean pa-
tient radiation exposure was 960  966 mGy. Both fluoros-
copy times and exposure to radiation decreased with
successive cases, indicating a learning curve in the process.
Patient 6 had a combined percutaneous coronaryery c February 2014
Patient 4 Patient 5 Patient 6 Patient 7 Mean (SD)/%
66 86 91 95 85.00  9.59
M F M M
1.26 1.41 1.00 2.00 1.41  0.55
N N N N 0
2.02 1.21 2.05 1.98 1.76  0.32
Y Y Y Y 100
Y Y Y Y 100
N N N N 0
3.40 0.98 2.20 1.70 1.60  1.00
4.48 1.25 2.87 2.64 2.30  1.42
III III III III
II I I I
59 46 55 20 45.14  17.87
Mild Moderate Severe Severe
0.70 0.34 0.60 0.70 0.62  0.13
109 63 51 67 74.86  23.28
58 40 34 40 41.43  10.45
1þ AI, 1þ MR 1þ AI, 1þ MR, 1þ TR 1þ AI, 1þ MR, 3þ TR 2þ MR, 2þ TR
Hodgkin’s lymphoma, chest
radiation, PVD, carotid
stenosis
CRF, asthma CVA, residual weakness,
atrial fibrillation, CAD
Atrial fibrillation, CRF,
COPD, pulmonary fibrosis
PVD, previous chest
radiation, s/p CABG
Small iliac arteries,
on home oxygen
Severe PVD, Jehovah’s
witness
Severe PVD, pulmonary
fibrosis, DLCO 40%
predicted
9.92 19.83 25.49 36.13 21.59  8.46
3.73 18.01 N/A 24.34 16.81  6.87
TABLE 1. Continued
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longer fluoroscopy time and higher radiation. The meanTABLE 2. Procedure variables
Parameter Patient 1 Patient 2 Patient 3 Patie
Access Mini-
sternotomy
4th space
Mini-
sternotomy
4th space
Mini-
sternotomy
3rd space
Mini–
anterio
thoraco
right 3
Fluoroscopy
time (min)
28.1 21.6 11.8 16
Radiation (mGy) 1708 2823 685.3 672
Good valve
positioning
Y Y Y Y
Conversion
to surgical
replacement
N N N N
Reexploration
for bleeding
N N N N
Use of CPB/IABP N N N N
SD, Standard deviation; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon pump.
The Journal of Thoracic and Caradiation exposure is less than for transfemoral TAVR at
the Cleveland Clinic.nt 4 Patient 5 Patient 6 Patient 7 Mean ± SD/%
r
tomy
rd space
Mini-
sternotomy
3rd space
Mini-
sternotomy
4th space
Left
subclavian
artery
.4 12.2 28.9 13.0 18.86  7.39
.8 261.8 1874 385 960  966
Y Y Y 100
N N N 0
N N N 0
N N N 0
rdiovascular Surgery c Volume 147, Number 2 647
TABLE 3. Outcomes
Parameter Patient 1 Patient 2 Patient 3 Patient 4
Mechanical ventilation (d) 0 20 1 1
ICU stay (d) 1 23 2 2
Hospital stay (d) 7 51 9 5
Postoperative echocardiogram
Peak AV gradient (mm Hg) 21 53 26 15
Mean AV gradient (mm Hg) 12 29 12 7
Valvular insufficiency 2þ AI para post jet Trivial AI 2þ AI para post Trivial AI
Stroke/TIA N N N N
Reexploration for bleeding N N N N
Postoperative complications B/L pleural effusion, increased
creatinine, no dialysis
Respiratory failure, PTX, trachea,
DVT
Second-degree AVB (PPM), left
pleural effusion
None
Discharge destination Skilled nursing facility Skilled nursing facility Home with nursing help Home
30 d Readmit32 for increase swelling
for fluid overload
Patient admission>30 d No issues No issues
SD, Standard deviation; CI, confidence interval; ICU, intensive care unit; AV, aortic valve; TIA, transient ischemic attack; AI, aortic insufficiency; B/L, bilateral;
PTX, pneumothorax; DVT, deep vein thrombosis; AVB, atrioventricular block; PPM, permanent pacemaker; TR, tricuspid regurgitation; RRT, renal replacement therapy.
Acquired Cardiovascular Disease Al Kindi et al
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Table 3 shows the postoperative course. Three patients
were extubated in the operating room. Another 3 patients
were extubated within hours to intensive care unit (ICU) ad-
mission, ranging from 2 to 6 hours. Patient 2, who had ex-
treme restrictive lung disease (FEV1, 0.71; forced vital
capacity, 0.96) was initially extubated on postoperative
day 2 but then had to be reintubated for respiratory failure.
She eventually was weaned from the ventilator 20 days after
undergoing a tracheostomy. She was decannulated before
discharge.
The median ICU stay was 2 days (interquartile range,
1.89 to 12.75).The median hospital stay was 7 days (inter-
quartile range, 1.08 to 29.65). None of the patients re-
quired reexploration for bleeding.
There was zero procedural and 30-day mortality. The in-
cidence of transient ischemic attack and stroke was also
zero. Two patients had worsening renal function that did
not require dialysis. Two patients also had pleural effusions
and required bedside thoracentesis. One patient had heart
block and required a transvenous permanent pacemaker.
One patient had deep vein thrombosis that required antico-
agulation for 3 months.
All patients received a complete echocardiographic eval-
uation before discharge or within 30 days of the procedure.
Postoperative echocardiogram showed a significant de-
crease of peak AV gradient from 74.86  23.28 to 21.86
 14.90 (P ¼ .003) and a significant decrease in mean
AV gradient from 41.43  10.45 to 11.43  8.46
(P ¼ .004). Some of the implanted valves showed evidence
of aortic insufficiency. Three patients had 2þ paravalvular
leak, and the remaining patients had 1þ or less aortic insuf-
ficiency. Those with significant paravalvular leaks found on
operative TEE were reballooned immediately. No patient648 The Journal of Thoracic and Cardiovascular Surgwas returned for reballooning if follow-up echocardiogram
showed aortic insufficiency.
Despite the high surgical risk of the study population, 3 of
the patients were eventually discharged home. The other 4
patientswere discharged to a skilled nursing facility. Two pa-
tients were readmitted within 30 days, 1 with fluid overload
that responded to diuresis. The other patient with pericarditis
was managed successfully with anti-inflammatory agents.
DISCUSSION
Aortic stenosis in the elderly is a common occurrence in
the general population, with the prevalence in adults aged
75 years or more estimated at 4.6%.5 In modern medicine,
few diseases have the symptomatic and survival benefit of
SAVR in AS. However, given that degenerative AS is a dis-
ease of old age, a good proportion of patients do not undergo
SAVR because of high operative morbidity and mortality.
The European Heart Survey showed that only 31.8% of pa-
tients underwent AV replacement. In another study from
southern California, 61% of patients with critical aortic ste-
nosis never underwent SAVR.6 Various reasons may be
behind deferring surgical intervention, but increased surgi-
cal risk from comorbidities is probably one of the leading
causes. For instance, coronary artery disease occurs in
more than 50% of patients with AS who are aged 70 years
or more. This number increases to more than 65% in those
aged 80 years or more.7 Coronary artery disease has been
shown to be an independent predictor of increased mortality
in patients undergoing SAVR.8,9
With medical management, patients do poorly, with ap-
proximately 50% of symptomatic patients not surviving
their first year. In the pre-TAVR era, balloon aortic valvulo-
plasty (BAV) was used as an attempt to resolve symptoms
and affect survival. However, the procedure has a 17%ery c February 2014
Patient 5 Patient 6 Patient 7 Mean ± SD/median (95% CI)
0 1 0 1 (3.55 to 10.12)
6 2 2 2 (1.89 to 12.75)
16 6 6 7 (1.08 to 29.65)
9 18 11 21.86  14.90
3 11 6 11.43  8.46
No AI 2þ AI, 2þ TR 1þ AI
N N N
N N N
Acute on chronic renal failure, no
RRT
Poor mobility Residual stroke None
Skilled nursing facility Home Skilled nursing facility
No issues Readmitted for left chest pain,
pericarditis
No issues
TABLE 3. Continued
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cause the rate of restenosis is high. The survival benefit of
BAV is only seen in those who were bridged to SAVR
who have a 78% 1-year survival compared with 44% in pa-
tients not undergoing surgery.5
Given the poor outcome of BAValone and with SAVR be-
ing a predictor for survival, there was a need for less-
invasive aortic intervention for high-risk patients. Since
the first successful clinical report by Cribier and colleagues4
in 2002, TAVR has progressed rapidly from the transseptal
venous approach to transfemoral10 and transapical6,10
approaches. With each new approach, a number of
advantages but also limitations appeared.
The initial results of TAVR were promising, both short
and mid-term, proving the feasibility of the procedure and
clinical benefits. In the 1-year report by the PARTNER trial
investigators, TAVR was not inferior to SAVR. The 30-day
mortality in those with TAVR was lower than in the surgical
group but did not reach statistical significance. However, at
1 year, TAVR had survival similar to that for SAVR.11 These
findings were seen again in the 2-year report in which the
survival was similar in the 2 groups.12
However, although these 2 reports proved the feasibility
and noninferiority of TAVR via the transfemoral and the
transapical approaches, there were inherent problems with
this new technology compared with traditional SAVR.
The rate of all neurologic events was higher in the TAVR
group than in the SAVR group at 30 days (5.5% vs 2.4%,
P ¼ .04) and at 1 year (8.3% vs 4.3%, P ¼ .04). The rate
of major stroke was higher in the TAVR group but did not
reach statistical significance.11 At 2 years, the frequency
of stroke did not differ significantly between the 2 groups
(hazard ratio, 1.22; 95% confidence interval, 0.67-2.23).12
The fact that the risk of neurologic events is higher ini-
tially in the TAVR group and then normalizes toward thatThe Journal of Thoracic and Caof the surgical group beyond 30 days indicates that this
is probably inherent to the surgical technique used
rather than patient-related factors.13 In addition to its decre-
menting effect on the quality of life, stroke greatly increases
the hazard of death,12with 43%of patientswith a neurologic
event ultimately expiring comparedwith 29% of thosewith-
out.13 Thus, it is important that approaches in TAVR im-
prove to reduce the rate of stroke. In the transfemoral
approach, the incidence of periprocedural neurologic events
is attributed to manipulation of wires and catheters in the
arch. Thus, the increased rate of stroke in patients with asso-
ciated coronary artery disease who generally have an in-
creased incidence of peripheral calcification.14 In addition,
for unclear reasons, it has been observed that assignment
to a transapical approach because of not being a candidate
for a transfemoral approach is a strong predictor for neuro-
logic events.13 Direct cannulation of the ascending aorta
avoids manipulation of wires and catheters in the arch. Al-
though our sample size is small, we do not have any docu-
mented neurologic events in the first 30 days. The
ascending aorta is assessed for disease from the preoperative
computed tomography scan, intraoperative direct palpation
for calcium-free area, and, if needed, intraoperative peri-
aortic ultrasound. The degree of manipulation of the aorta
is minimal throughout the procedure. This technique still
does not eliminate the risk of stroke from deploying the
valve and crushing the severely calcified AV.
Vascular access complication is an important issue in the
transfemoral TAVR approach. Even in minimal procedures
such as BAV, the rate of access-site complications requiring
surgery was 6%.12 Dewey and colleagues14 reported lower
transfemoral TAVR access-site complications of 2.3% to
4.8%. However, in the PARTNER trial, the incidence of
any vascular complication was 17%, of which 11% have
been classified as major.11,12 In this report, we did notrdiovascular Surgery c Volume 147, Number 2 649
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with direct vision of the aorta, and the cannulation site is re-
paired with a purse-string suture and checked for hemosta-
sis and repaired before closure.
With the subclavian approach, the potential advantage
is that the artery tends to be devoid of significant calcifi-
cation and generally less tortuous compared with the iliac
artery. The subclavian artery is a fragile vessel, but repairs
of injuries are less invasive than that of iliac artery. The
subclavian approach has been described with the Core-
Valve (Medtronic Inc, Minneapolis, Minn).15 The Core-
Valve can be delivered only in a retrograde fashion and
has a flexible sheath design that allows better manipulation
in tortuous vessels. However, the SAPIEN valve can be
delivered both antegrade and retrograde.
Bapat and colleagues16 reported using a transaortic
approach for the Sapien valve with good results. In a recent
study by Bruschi and colleagues17 from Milan, the authors
describe the use of the CoreValve via direct aortic cannula-
tion via amini-right thoracotomy approach. The authors had
excellent 30-day outcome. Compared with our report, there
was no mention of respiratory complications, such as pro-
longed ventilation and ICU stay. Poor vascular access and
respiratory concerns were the main determinants in the se-
lected approach. The transfemoral SAPIEN valve, as men-
tioned earlier, has inherent design differences compared
with the CoreValve that pose different technical issues if de-
livered directly transaortic or via the subclavian artery.17
Although the transapical approach avoids peripheral ac-
cess issues, it also has its own limitations. The left ventricular
puncture carries the risk of a major tear and bleeding, espe-
cially in this age group, requiring conversion and going on
CPB to repair the defect. The TRAVERCE trial reports an in-
cidence of 4.8% of access site complications,18 with others
reporting delayed bleeding and pseudoaneurysm forma-
tion.19,20 Manipulation of the ventricular muscle carries the
risk of hemodynamic instability, requiring the use of CPB
during the procedure and intra-aortic balloon pump in up to
8% of patients.6,21 There is no direct manipulation of the
ventricle with the transaortic and subclavian approaches,
and the risk of ventricular injury is low. None of our
patients required CPB for hemodynamic instability or
repair of access site. In addition, none required an intra-
aortic balloon pump postoperatively for hemodynamic
instability.
One of the main limitations of the transapical approach is
the anterior lateral thoracotomy to access the left ventricular
apex. Thoracotomy incisions are known to be painful. The
performance of this incision in patients with poor pulmo-
nary function runs the risk of postoperative respiratory fail-
ure as a result of anatomic deformity of the chest wall,
anatomic collapse of areas of the left lung, and increased
pain that interfere with good respiratory efforts in the pa-
tient. The mini-sternotomy approach has been shown to650 The Journal of Thoracic and Cardiovascular Surghave better ventilator outcomes when compared with the
anterolateral thoracotomy.22,23 Except for 1 patient who
required prolonged ventilation, our median ventilation
time was less than 1 day despite the poor respiratory
function of some of the patients. These approaches also
allow safer access, avoiding encountering the lung and
causing prolonged air leak in patients with previous
surgeries or radiation therapy to the chest wall.
CONCLUSIONS
The current report has a limited number of patients with
a limited follow-up and no direct comparison made with
conventional open surgical replacement or other transcath-
eter approaches. However, these approaches are promising
and offer alternative options in patients with no access
and prohibitive chest pathology or pulmonary function.
They warrant being investigated further with a larger sam-
ple size and longer follow-up.
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